Home › Research › Down syndrome and Alzheimer's
Present and future of Alzheimer therapy
Giacobini E.. Journal of neural transmission. Supplementum, 2000-01-01
Topic: Amyloid, tau and blood-test diagnosis
Three major lines of drugs have been developed or are under development for the treatment of Alzheimer Disease (AD): cholinergic drugs (mainly cholinesterase inhibitors), anti-beta-amyloid drugs, estrogens and anti-inflammatories. Cholinesterase inhibitors are the only drugs presently approved in USA and Europe for the indication of AD. Cholinesterase inhibitors tested in clinical trials in Europe, USA and Japan include less than ten drugs, however most of these compounds have advanced to clinical trials III. Based on results related to a population of over 8,000 patients we conclude that several of these compounds have shown significant clinical efficacy and safety in the treatment of Alzheimer disease. There are, however, differences with regard to side effects. The major clinical effect is stabilization of cognitive function during a six- to 12-months period with a parallel improvement of behavioral symptoms. Long-term effect of cholinesterase inhibitors extending to a two year-period has been reported. Future applications of these drugs are treatment of other types dementias such as Lewy body dementia, vascular dementia and Down Syndrome dementia. Combination of cholinesterase inhibitors with estrogens, anti-oxidants and anti-inflammatories may represent a further improvement of the therapy. From the economical point of view, treatment with cholinesterase inhibitors is not cost neutral.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Giacobini, E. (2000). Present and future of Alzheimer therapy. Journal of neural transmission. Supplementum. https://doi.org/10.1007/978-3-7091-6781-6_24
Vancouver
Giacobini E. Present and future of Alzheimer therapy. Journal of neural transmission. Supplementum. 2000. doi:10.1007/978-3-7091-6781-6_24. PMID: 10961434.
BibTeX
@article{giacobini2000-10961434,
author = {Giacobini, E.},
title = {{Present and future of Alzheimer therapy}},
journal = {Journal of neural transmission. Supplementum},
year = {2000},
doi = {10.1007/978-3-7091-6781-6_24},
pmid = {10961434},
url = {https://doi.org/10.1007/978-3-7091-6781-6_24}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Based on results related to a population of over 8,000 patients we conclude that several of these compounds have shown significant clinical efficacy and safety in the treatment of Alzheimer disease.
Why it matters
This review states that cholinesterase inhibitors were the only drugs then approved for Alzheimer's disease and that several showed significant clinical efficacy and safety, mainly stabilizing cognitive function for six to 12 months. It also discusses future possibilities such as combining these drugs with estrogens, antioxidants and anti-inflammatories, and treating other dementias including Down syndrome dementia.
Study details
- Participants8,000
- Evidence strengthLow
How this study scored 38/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it. We have no data on journal's citation record, so that was left out: it earned 36 of the 96 points we could judge it on, which is 38 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of neural transmission. Supplementum) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2000 — older than 20 years, still counted |
| Sample size | 3 / 4 | 8,000 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 20 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.7 citations a year over 28 year(s) since 2000 |
| Impact for its field and year | 3 / 6 | Cited 8.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Ezio Giacobini: h-index 45 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | University Hospital of Geneva: institution h-index 635 (OpenAlex) |
| Multi-centre collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 10961434) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 36 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 36 of the 96 points we could judge it on is 38 out of 100. |
| Total | 38 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Down syndrome and Alzheimer's
Also in Down syndrome and Alzheimer's
12 studies in the library are filed under Down syndrome and Alzheimer's with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Down syndrome and Alzheimer's hub.